The vaccines market is likely to strengthen its boundaries at an average CAGR of 6.6% during the forecast period. The market is expected to hold a value of US$ 42.7 billion in 2023 while it is anticipated to cross a value of US$ 80.8 billion by 2033.
The research report on the vaccines market explains that the Covid-19 spread turning into a full-fledged pandemic has fueled the demand for vaccines. Furthermore, governments investing huge capital in progressive healthcare systems are anticipated to expand the vaccine market size. Government healthcare programs deliver vaccines to infants to provide them with prevention from chronic diseases like tuberculosis, rotavirus, etc. The rise in new diseases like H1B1 infection, and swine flu (H1N1) is pushing the authorities to adopt new methods that help in preventing the diseases.
The vaccines market outlook states that the rising incidence of diseases worldwide is encouraging the adoption of vaccines, thereby creating prospects for the growth of the vaccines market. Deadly diseases such as tuberculosis, cancer, influenza, and pneumonia have high fatality rates, which is compelling people to opt for vaccinations. For instance, as per the World Health Organization (WHO), around 1.5 million people died from tuberculosis in 2020 while over 10 million people fell ill with TB. Additionally, increasing public awareness about the benefits of vaccination along with rising government support in research and development is likely to act as a catalyst for the growth of the vaccines market.
Attributes
Details
Vaccines Market CAGR (2023 to 2033)
6.6%
Vaccines Market Size (2023)
US$ 42.7 billion
Vaccines Market Size (2033)
US$ 80.8 billion
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
How is the Future Outlook (2023 to 2033) for the Vaccines Market in Comparison to the Historical Pattern (2017 to 2022)
Short-term Growth: Factors such as the rising prevalence of chronic and infectious diseases, increase in immunization programs, advancements in vaccine technology, and changing attitudes towards vaccines are some of the key factors expected to drive the growth in the vaccines market during the forecast period.
Since their invention, vaccines have completely revolutionized the healthcare industry across the world. They have become ideal healthcare preventive products used for enhancing immunity against numerous diseases. Expansion of the prevention vaccines market and growing awareness among people in developing regions about the benefits of vaccines is likely to boost the vaccines market growth.
Mid-term Growth: The rising need for protecting children from deadly chronic and infectious diseases like tuberculosis, cancer, hepatitis, influence, etc. is expected to create lucrative opportunities for vaccine manufacturers during the forecast period. According to the United Nations Children’s Fund (UNICEF), each year vaccination saves 2 to 3 million children from deadly diseases.
Vaccine manufacturing giants like Pfizer and GSK are vigorously investing in vaccine research and development for introducing new products with a highly effective nature. Besides this, they are holding various trials for establishing the safety and efficacy of vaccines. For instance, in January 2022, Pfizer Inc., and BioNTech SE initiated a clinical study to evaluate the safety, immunogenicity, and tolerability of an Omicron-based vaccine candidate in adults aged 18 to 55. The market is anticipated to thrive at a significant CAGR between 2022 and 2028.
Long-term Growth: Rapidly evolving technology has a profound impact on vaccine market trends. Developments like the introduction of genetic engineering and lab automation are helping vaccine manufacturers to develop low-cost vaccines, which may attract markets and eventually enable vaccine market access.
Additionally, various initiatives taken by governments of emerging nations for launching mass vaccination drives may augment the overall vaccines industry worth in the future. Global vaccine demand is anticipated to rise at 6.6% CAGR during the forecast period from 2023 and 2033.
Which Factors Are Challenging the Vaccine Market Growth?
High Capital Investments and Low Purchasing Power in Emerging Markets May Impede Market Development.
The development of vaccines is a lengthy, complicated, and expensive process. As a result, most of the vaccines are usually costlier, which is acting as a key hurdle in the growth of the vaccines market. Similarly, lack of awareness and poor healthcare infrastructure across developing regions have also hampered vaccine market access.
Find your sweet spots for generating winning opportunities in this market.
Comparative View of the Vaccines Market
Vaccines Market:
Attributes
Vaccines Market
CAGR (2023 to 2033)
6.6%
Market Value (2033)
US$ 80.8 billion
Growth Factor
Increased healthcare budget post-pandemic along with the extended research and development programs fuels the demand for the vaccines market.
Opportunity
The increased opportunities are promoted through advanced DNA and RNA-based vaccines.
Key Trends
The gene-based vaccines along with immunization and immunotherapy shape new trends in the market.
Influenza Vaccine Market:
Attributes
Influenza Vaccine Market
CAGR (2023 to 2033)
8.8%
Market Value (2033)
US$ 18.89 billion
Growth Factor
The development of combination vaccines along with the development of mRNA vaccines is gaining traction in the influenza vaccine market.
Opportunity
Inactivated influenza vaccine and its effective results are creating opportunities for the market.
Key Trends
The rising cases of Covid-19 cases have shaped the sales of influenza vaccines globally.
Coronavirus (Covid-19) Current Therapy Market:
Attributes
Coronavirus (Covid -19) Current Therapy Market
CAGR (2023 to 2033)
19.8%
Market Value (2033)
US$ 150.28 million
Growth Factor
Higher sales of anti-viral drugs like remdesivir and RNA-based medications are fueling the sales of coronavirus current therapy solutions.
Opportunity
The increasing testing and rising awareness around Covid-19 and its implications are creating opportunities for the market
Key Trends
Advanced convalescent plasma therapy is shaping trends in the coronavirus therapy market.
Vaccines Market Country-wise Insights
Regions
Absolute Market Growth
United States
US$ 14.8 billion
United Kingdom
US$ 1.5 billion
China
US$ 3.5 billion
Japan
US$ 2.3 billion
India
US$ 1.3 billion
Which Region leads the Market in terms of Market Share?
Higher Healthcare Budget post Pandemic along with the Presence of Vaccine Giants propels the Regional Growth
United States Market CAGR (2023 to 2033)
6.6%
United States Market Absolute Doller Growth (US$ million/billion)
US$ 14.8 billion
The United States is the leading market for vaccines in 2023 and is forecast to grow at a prolific CAGR over the forecast period, owing to the presence of leading vaccine manufacturers, increasing investments in research and development, continuous vaccine launches and approvals, availability of highly advanced technologies, awareness among people about latest vaccines market trends, and expansion of veterinary vaccines market. The United States market is expected to thrive at a CAGR of 6.6% between 2023 and 2033.
Similarly, the rising incidence of infectious and chronic diseases in the country has become a crucial factor in boosting vaccine market growth. According to the Centers for Disease Control and Prevention (CDC), around 6,400,000 to 11,000,000 flu illnesses cases were recorded between October 1, 2021, through May 7, 2022, in the United States.
People in the United States are spending large amounts on vaccines to make themselves immune to various diseases. Thus, growing concerns about rising cases of various infectious diseases and positive attitudes toward vaccines may significantly increase the vaccine industry worth in the future.
Furthermore, increasing government initiatives coupled with the expansion of the COVID-19 vaccine market size are expected to boost the growth of the vaccine market in the United States during the forthcoming period. The market is anticipated to reach a value of US$ 31.4 billion by 2033.
What makes China a Leading Vaccines Market in terms of CAGR?
Changing Attitudes Towards Vaccines and Favorable Government Support Creating Space for Vaccine Market Growth in China
Region
Attributes
Chinese Market CAGR (2023 to 2033)
8.9%
Chinese Market Absolute Doller Growth (US$ million/billion)
US$ 3.5 billion
As per FMI, the vaccines market in China is poised to exhibit strong on the back of increasing government spending for immunization programs, changing attitudes of people towards vaccinations, rise in the development of novel vaccines, the emergence of new vaccine market trends, the surge in various diseases, and expansion of meningococcal vaccines market in the country. The Chinese market is likely to expand at a CAGR of 8.9% between 2023 and 2033 while it is expected to cross a value of US$ 6.0 billion by 2033.
Furthermore, the rapidly growing population and rising health awareness among people in the country are making a conducive environment for the growth of the vaccine market.
Demand for vaccines was especially high during the COVID-19 pandemic and it is expected to continue at a steady pace during the post-pandemic period as people's attitude towards vaccines takes a positive turn.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
Segment
Top Vaccine Type
Top Sub-segment
Subunit & Conjugate
CAGR (2017 to 2022)
5.8%
CAGR (2023 to 2033)
7.3%
Segment
Route of Administration
Top Sub-segment
Injectable
CAGR (2017 to 2022)
6.0%
CAGR (2023 to 2033)
6.7%
Highly Applicable for Infants, Conjugate Vaccines work on the Antigen Hiding Prospects
As per FMI, the conjugate vaccines segment accounted for the leading share of the global vaccine market by vaccine type due to increased spending by government and private companies on its development. Rising preference for conjugate vaccines is due to their various additional features including greater antibody persistence and avidity. The segment is likely to thrive at a CAGR of 7.3% between 2023 and 2033.
Growing demand for conjugate vaccines due to their ability to provide long-lasting immunity against diseases may continue to offer lucrative opportunities to vaccine manufacturers during the forecast period, thereby boosting vaccines market growth
Effective, Faster, and Efficient Route of Administration Drive Injectable Type Vaccines
Based on the route of administration, injectable (intramuscular and subcutaneous) routes are the most preferred methods used by medical professionals globally. These routes are especially ideal when larger volumes of drugs are to be administrated into the body.
Administration of drugs through the intramuscular route offers various benefits which include rapid absorption and less pain. The segment thrives at a CAGR of 6.7% between 2023 and 2033.
Competition Scenario
Leading players are continuously investing in research and development activities for introducing novel vaccines with long-term efficacy. Besides this, they are adopting growth strategies such as new product launches and approvals, partnerships, acquisitions, and strengthening of distribution channels to expand their global footprint.
Recent Market Developments
In 2021, MSD Pharmaceuticals, a wholly-owned subsidiary of Merck Sharp & Dohme, launched Gardasil 9, India’s first gender-neutral HPV vaccine.
In April 2020, the United States Food and Drug Administration (FDA), approved Sanofi’s MenQuadfi vaccine for the prevention of invasive meningococcal diseases in persons aged 2 years and older.
In 2021, Abbott launched a new inactivated quadrivalent vaccine for influenza in India that offers protection against four virus strains, in India.
Key Contributors to the Vaccines Market
Merck & Co., Inc
GlaxoSmithKline
Pfizer BioNTech
Sanofi SA
CSL Limited
Emergent Biosolutions Inc.
Johnson & Johnson (J&J)
AstraZeneca plc
Bavarian Nordic A/S
Mitsubishi Tanabe Pharma Corporation.
Out of these GSK
Pfizer
Mark
Sanofi
Key Segments
By Vaccine Type:
Inactivated
Live attenuated
Recombinant
Toxoid
Subunit & Conjugate
By Valance:
Monovalent
Multivalent
By Route of Administration:
Injectable
Oral
By Indication:
Influenza
Pneumococcal Diseases
Human Papillomavirus
Meningococcal Diseases
Rotavirus
MMR
Hepatitis
DTP
Polio
By Distribution Channel:
Hospital Pharmacies
Institutional Sales
Retail Pharmacies
By Region:
North America
Latin America
Europe
Asia Pacific (APAC)
The Middle East & Africa (MEA)
Frequently Asked Questions
The vaccines market is expected to reach US$ 42.7 billion in 2023.
The market is anticipated to expand at a CAGR of 6.6%.
The emergence of gene-based vaccines in addition to immunotherapy and immunization.
The advent of RNA and DNA-based vaccines are yielding significant opportunities.
The China market is expected to expand at a CAGR of 8.9% through 2033.
Table of Content
1. Executive Summary | Vaccines Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Vaccine Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Vaccine Type, 2017 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Vaccine Type, 2023 to 2033
5.3.1. Inactivated
5.3.2. Live Attenuated
5.3.3. Toxoid
5.3.4. Subunit & Conjugate
5.3.5. Others
5.4. Y-o-Y Growth Trend Analysis By Vaccine Type, 2017 to 2022
5.5. Absolute $ Opportunity Analysis By Vaccine Type, 2023 to 2033
6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Valance
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Valance, 2017 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Valance, 2023 to 2033
6.3.1. Monovalent
6.3.2. Multivalent
6.4. Y-o-Y Growth Trend Analysis By Valance, 2017 to 2022
6.5. Absolute $ Opportunity Analysis By Valance, 2023 to 2033
7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Indication , 2017 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication , 2023 to 2033
7.3.1. DTP
7.3.2. Hepatitis
7.3.3. Human Papillomavirus
7.3.4. Influenza
7.3.5. Meningococcal Disease
7.3.6. MMR
7.3.7. Pneumococcal Disease
7.3.8. Polio
7.3.9. Rotavirus
7.3.10. Others
7.4. Y-o-Y Growth Trend Analysis By Indication , 2017 to 2022
7.5. Absolute $ Opportunity Analysis By Indication , 2023 to 2033
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route of Administration
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2017 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
8.3.1. Injectable
8.3.1.1. Intramuscular
8.3.1.2. Subcutaneous
8.3.2. Oral
8.3.3. Others
8.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017 to 2022
8.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
9.1. Introduction / Key Findings
9.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2017 to 2022
9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
9.3.1. Hospital Pharmacies
9.3.2. Institutional Sales
9.3.3. Retail Pharmacies
9.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017 to 2022
9.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region
10.1. Introduction
10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2022
10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. Asia Pacific
10.3.5. Middle East and Africa
10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. The USA
11.2.1.2. Canada
11.2.2. By Vaccine Type
11.2.3. By Valance
11.2.4. By Indication
11.2.5. By Route of Administration
11.2.6. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Vaccine Type
11.3.3. By Valance
11.3.4. By Indication
11.3.5. By Route of Administration
11.3.6. By Distribution Channel
11.4. Key Takeaways
12. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Brazil
12.2.1.2. Mexico
12.2.1.3. Rest of Latin America
12.2.2. By Vaccine Type
12.2.3. By Valance
12.2.4. By Indication
12.2.5. By Route of Administration
12.2.6. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Vaccine Type
12.3.3. By Valance
12.3.4. By Indication
12.3.5. By Route of Administration
12.3.6. By Distribution Channel
12.4. Key Takeaways
13. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Germany
13.2.1.2. United Kingdom (UK)
13.2.1.3. France
13.2.1.4. Spain
13.2.1.5. Italy
13.2.1.6. Rest of Europe
13.2.2. By Vaccine Type
13.2.3. By Valance
13.2.4. By Indication
13.2.5. By Route of Administration
13.2.6. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Vaccine Type
13.3.3. By Valance
13.3.4. By Indication
13.3.5. By Route of Administration
13.3.6. By Distribution Channel
13.4. Key Takeaways
14. Asia Pacific Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. India
14.2.1.3. Thailand
14.2.1.4. Singapore
14.2.1.5. Australia
14.2.1.6. Rest of Asia Pacific
14.2.2. By Vaccine Type
14.2.3. By Valance
14.2.4. By Indication
14.2.5. By Route of Administration
14.2.6. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Vaccine Type
14.3.3. By Valance
14.3.4. By Indication
14.3.5. By Route of Administration
14.3.6. By Distribution Channel
14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of Middle East and Africa
15.2.2. By Vaccine Type
15.2.3. By Valance
15.2.4. By Indication
15.2.5. By Route of Administration
15.2.6. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Vaccine Type
15.3.3. By Valance
15.3.4. By Indication
15.3.5. By Route of Administration
15.3.6. By Distribution Channel
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Vaccine Type
16.1.2.2. By Valance
16.1.2.3. By Indication
16.1.2.4. By Route of Administration
16.1.2.5. By Distribution Channel
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Vaccine Type
16.2.2.2. By Valance
16.2.2.3. By Indication
16.2.2.4. By Route of Administration
16.2.2.5. By Distribution Channel
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Vaccine Type
16.3.2.2. By Valance
16.3.2.3. By Indication
16.3.2.4. By Route of Administration
16.3.2.5. By Distribution Channel
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Vaccine Type
16.4.2.2. By Valance
16.4.2.3. By Indication
16.4.2.4. By Route of Administration
16.4.2.5. By Distribution Channel
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Vaccine Type
16.5.2.2. By Valance
16.5.2.3. By Indication
16.5.2.4. By Route of Administration
16.5.2.5. By Distribution Channel
16.6. UK
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Vaccine Type
16.6.2.2. By Valance
16.6.2.3. By Indication
16.6.2.4. By Route of Administration
16.6.2.5. By Distribution Channel
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Vaccine Type
16.7.2.2. By Valance
16.7.2.3. By Indication
16.7.2.4. By Route of Administration
16.7.2.5. By Distribution Channel
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Vaccine Type
16.8.2.2. By Valance
16.8.2.3. By Indication
16.8.2.4. By Route of Administration
16.8.2.5. By Distribution Channel
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Vaccine Type
16.9.2.2. By Valance
16.9.2.3. By Indication
16.9.2.4. By Route of Administration
16.9.2.5. By Distribution Channel
16.10. China
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Vaccine Type
16.10.2.2. By Valance
16.10.2.3. By Indication
16.10.2.4. By Route of Administration
16.10.2.5. By Distribution Channel
16.11. India
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Vaccine Type
16.11.2.2. By Valance
16.11.2.3. By Indication
16.11.2.4. By Route of Administration
16.11.2.5. By Distribution Channel
16.12. Thailand
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Vaccine Type
16.12.2.2. By Valance
16.12.2.3. By Indication
16.12.2.4. By Route of Administration
16.12.2.5. By Distribution Channel
16.13. Singapore
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Vaccine Type
16.13.2.2. By Valance
16.13.2.3. By Indication
16.13.2.4. By Route of Administration
16.13.2.5. By Distribution Channel
16.14. Australia
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Vaccine Type
16.14.2.2. By Valance
16.14.2.3. By Indication
16.14.2.4. By Route of Administration
16.14.2.5. By Distribution Channel
16.15. GCC Countries
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Vaccine Type
16.15.2.2. By Valance
16.15.2.3. By Indication
16.15.2.4. By Route of Administration
16.15.2.5. By Distribution Channel
16.16. South Africa
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Vaccine Type
16.16.2.2. By Valance
16.16.2.3. By Indication
16.16.2.4. By Route of Administration
16.16.2.5. By Distribution Channel
16.17. Israel
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Vaccine Type
16.17.2.2. By Valance
16.17.2.3. By Indication
16.17.2.4. By Route of Administration
16.17.2.5. By Distribution Channel
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Vaccine Type
17.3.3. By Valance
17.3.4. By Indication
17.3.5. By Route of Administration
17.3.6. By Distribution Channel
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Sanofi SA
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Merck & Co., Inc
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Pfizer BioNTech
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. CSL Limited
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Johnson & Johnson
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Emergent Biosolutions Inc.
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. AstraZeneca plc
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Bavarian Nordic A/S
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Mitsubishi Tanabe Pharma Corporation
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Serum Institute of India Pvt. Ltd.
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2017 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Vaccine Type, 2017 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Valance, 2017 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Indication , 2017 to 2033
Table 5: Global Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2033
Table 6: Global Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Country, 2017 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Vaccine Type, 2017 to 2033
Table 9: North America Market Value (US$ Million) Forecast by Valance, 2017 to 2033
Table 10: North America Market Value (US$ Million) Forecast by Indication , 2017 to 2033
Table 11: North America Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2033
Table 12: North America Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2033
Table 13: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2033
Table 14: Latin America Market Value (US$ Million) Forecast by Vaccine Type, 2017 to 2033
Table 15: Latin America Market Value (US$ Million) Forecast by Valance, 2017 to 2033
Table 16: Latin America Market Value (US$ Million) Forecast by Indication , 2017 to 2033
Table 17: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2033
Table 18: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2033
Table 19: Europe Market Value (US$ Million) Forecast by Country, 2017 to 2033
Table 20: Europe Market Value (US$ Million) Forecast by Vaccine Type, 2017 to 2033
Table 21: Europe Market Value (US$ Million) Forecast by Valance, 2017 to 2033
Table 22: Europe Market Value (US$ Million) Forecast by Indication , 2017 to 2033
Table 23: Europe Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2033
Table 24: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2033
Table 25: Asia Pacific Market Value (US$ Million) Forecast by Country, 2017 to 2033
Table 26: Asia Pacific Market Value (US$ Million) Forecast by Vaccine Type, 2017 to 2033
Table 27: Asia Pacific Market Value (US$ Million) Forecast by Valance, 2017 to 2033
Table 28: Asia Pacific Market Value (US$ Million) Forecast by Indication , 2017 to 2033
Table 29: Asia Pacific Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2033
Table 30: Asia Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2033
Table 31: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2017 to 2033
Table 32: Middle East and Africa Market Value (US$ Million) Forecast by Vaccine Type, 2017 to 2033
Table 33: Middle East and Africa Market Value (US$ Million) Forecast by Valance, 2017 to 2033
Table 34: Middle East and Africa Market Value (US$ Million) Forecast by Indication , 2017 to 2033
Table 35: Middle East and Africa Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2033
Table 36: Middle East and Africa Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Vaccine Type, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Valance, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Indication , 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 5: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 6: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Million) Analysis by Region, 2017 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 10: Global Market Value (US$ Million) Analysis by Vaccine Type, 2017 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by Vaccine Type, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by Vaccine Type, 2023 to 2033
Figure 13: Global Market Value (US$ Million) Analysis by Valance, 2017 to 2033
Figure 14: Global Market Value Share (%) and BPS Analysis by Valance, 2023 to 2033
Figure 15: Global Market Y-o-Y Growth (%) Projections by Valance, 2023 to 2033
Figure 16: Global Market Value (US$ Million) Analysis by Indication , 2017 to 2033
Figure 17: Global Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033
Figure 18: Global Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033
Figure 19: Global Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2033
Figure 20: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 21: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 22: Global Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2033
Figure 23: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 24: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 25: Global Market Attractiveness by Vaccine Type, 2023 to 2033
Figure 26: Global Market Attractiveness by Valance, 2023 to 2033
Figure 27: Global Market Attractiveness by Indication , 2023 to 2033
Figure 28: Global Market Attractiveness by Route of Administration, 2023 to 2033
Figure 29: Global Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 30: Global Market Attractiveness by Region, 2023 to 2033
Figure 31: North America Market Value (US$ Million) by Vaccine Type, 2023 to 2033
Figure 32: North America Market Value (US$ Million) by Valance, 2023 to 2033
Figure 33: North America Market Value (US$ Million) by Indication , 2023 to 2033
Figure 34: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 35: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 36: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 37: North America Market Value (US$ Million) Analysis by Country, 2017 to 2033
Figure 38: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 39: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 40: North America Market Value (US$ Million) Analysis by Vaccine Type, 2017 to 2033
Figure 41: North America Market Value Share (%) and BPS Analysis by Vaccine Type, 2023 to 2033
Figure 42: North America Market Y-o-Y Growth (%) Projections by Vaccine Type, 2023 to 2033
Figure 43: North America Market Value (US$ Million) Analysis by Valance, 2017 to 2033
Figure 44: North America Market Value Share (%) and BPS Analysis by Valance, 2023 to 2033
Figure 45: North America Market Y-o-Y Growth (%) Projections by Valance, 2023 to 2033
Figure 46: North America Market Value (US$ Million) Analysis by Indication , 2017 to 2033
Figure 47: North America Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033
Figure 48: North America Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033
Figure 49: North America Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2033
Figure 50: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 51: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 52: North America Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2033
Figure 53: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 54: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 55: North America Market Attractiveness by Vaccine Type, 2023 to 2033
Figure 56: North America Market Attractiveness by Valance, 2023 to 2033
Figure 57: North America Market Attractiveness by Indication , 2023 to 2033
Figure 58: North America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 59: North America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 60: North America Market Attractiveness by Country, 2023 to 2033
Figure 61: Latin America Market Value (US$ Million) by Vaccine Type, 2023 to 2033
Figure 62: Latin America Market Value (US$ Million) by Valance, 2023 to 2033
Figure 63: Latin America Market Value (US$ Million) by Indication , 2023 to 2033
Figure 64: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 65: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 66: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 67: Latin America Market Value (US$ Million) Analysis by Country, 2017 to 2033
Figure 68: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 69: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 70: Latin America Market Value (US$ Million) Analysis by Vaccine Type, 2017 to 2033
Figure 71: Latin America Market Value Share (%) and BPS Analysis by Vaccine Type, 2023 to 2033
Figure 72: Latin America Market Y-o-Y Growth (%) Projections by Vaccine Type, 2023 to 2033
Figure 73: Latin America Market Value (US$ Million) Analysis by Valance, 2017 to 2033
Figure 74: Latin America Market Value Share (%) and BPS Analysis by Valance, 2023 to 2033
Figure 75: Latin America Market Y-o-Y Growth (%) Projections by Valance, 2023 to 2033
Figure 76: Latin America Market Value (US$ Million) Analysis by Indication , 2017 to 2033
Figure 77: Latin America Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033
Figure 78: Latin America Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033
Figure 79: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2033
Figure 80: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 81: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 82: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2033
Figure 83: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 84: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 85: Latin America Market Attractiveness by Vaccine Type, 2023 to 2033
Figure 86: Latin America Market Attractiveness by Valance, 2023 to 2033
Figure 87: Latin America Market Attractiveness by Indication , 2023 to 2033
Figure 88: Latin America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 89: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 90: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 91: Europe Market Value (US$ Million) by Vaccine Type, 2023 to 2033
Figure 92: Europe Market Value (US$ Million) by Valance, 2023 to 2033
Figure 93: Europe Market Value (US$ Million) by Indication , 2023 to 2033
Figure 94: Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 95: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 96: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 97: Europe Market Value (US$ Million) Analysis by Country, 2017 to 2033
Figure 98: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 99: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 100: Europe Market Value (US$ Million) Analysis by Vaccine Type, 2017 to 2033
Figure 101: Europe Market Value Share (%) and BPS Analysis by Vaccine Type, 2023 to 2033
Figure 102: Europe Market Y-o-Y Growth (%) Projections by Vaccine Type, 2023 to 2033
Figure 103: Europe Market Value (US$ Million) Analysis by Valance, 2017 to 2033
Figure 104: Europe Market Value Share (%) and BPS Analysis by Valance, 2023 to 2033
Figure 105: Europe Market Y-o-Y Growth (%) Projections by Valance, 2023 to 2033
Figure 106: Europe Market Value (US$ Million) Analysis by Indication , 2017 to 2033
Figure 107: Europe Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033
Figure 108: Europe Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033
Figure 109: Europe Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2033
Figure 110: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 111: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 112: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2033
Figure 113: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 114: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 115: Europe Market Attractiveness by Vaccine Type, 2023 to 2033
Figure 116: Europe Market Attractiveness by Valance, 2023 to 2033
Figure 117: Europe Market Attractiveness by Indication , 2023 to 2033
Figure 118: Europe Market Attractiveness by Route of Administration, 2023 to 2033
Figure 119: Europe Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 120: Europe Market Attractiveness by Country, 2023 to 2033
Figure 121: Asia Pacific Market Value (US$ Million) by Vaccine Type, 2023 to 2033
Figure 122: Asia Pacific Market Value (US$ Million) by Valance, 2023 to 2033
Figure 123: Asia Pacific Market Value (US$ Million) by Indication , 2023 to 2033
Figure 124: Asia Pacific Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 125: Asia Pacific Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 126: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 127: Asia Pacific Market Value (US$ Million) Analysis by Country, 2017 to 2033
Figure 128: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 129: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 130: Asia Pacific Market Value (US$ Million) Analysis by Vaccine Type, 2017 to 2033
Figure 131: Asia Pacific Market Value Share (%) and BPS Analysis by Vaccine Type, 2023 to 2033
Figure 132: Asia Pacific Market Y-o-Y Growth (%) Projections by Vaccine Type, 2023 to 2033
Figure 133: Asia Pacific Market Value (US$ Million) Analysis by Valance, 2017 to 2033
Figure 134: Asia Pacific Market Value Share (%) and BPS Analysis by Valance, 2023 to 2033
Figure 135: Asia Pacific Market Y-o-Y Growth (%) Projections by Valance, 2023 to 2033
Figure 136: Asia Pacific Market Value (US$ Million) Analysis by Indication , 2017 to 2033
Figure 137: Asia Pacific Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033
Figure 138: Asia Pacific Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033
Figure 139: Asia Pacific Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2033
Figure 140: Asia Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 141: Asia Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 142: Asia Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2033
Figure 143: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 144: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 145: Asia Pacific Market Attractiveness by Vaccine Type, 2023 to 2033
Figure 146: Asia Pacific Market Attractiveness by Valance, 2023 to 2033
Figure 147: Asia Pacific Market Attractiveness by Indication , 2023 to 2033
Figure 148: Asia Pacific Market Attractiveness by Route of Administration, 2023 to 2033
Figure 149: Asia Pacific Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 150: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 151: Middle East and Africa Market Value (US$ Million) by Vaccine Type, 2023 to 2033
Figure 152: Middle East and Africa Market Value (US$ Million) by Valance, 2023 to 2033
Figure 153: Middle East and Africa Market Value (US$ Million) by Indication , 2023 to 2033
Figure 154: Middle East and Africa Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 155: Middle East and Africa Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 156: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033
Figure 157: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2017 to 2033
Figure 158: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 159: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 160: Middle East and Africa Market Value (US$ Million) Analysis by Vaccine Type, 2017 to 2033
Figure 161: Middle East and Africa Market Value Share (%) and BPS Analysis by Vaccine Type, 2023 to 2033
Figure 162: Middle East and Africa Market Y-o-Y Growth (%) Projections by Vaccine Type, 2023 to 2033
Figure 163: Middle East and Africa Market Value (US$ Million) Analysis by Valance, 2017 to 2033
Figure 164: Middle East and Africa Market Value Share (%) and BPS Analysis by Valance, 2023 to 2033
Figure 165: Middle East and Africa Market Y-o-Y Growth (%) Projections by Valance, 2023 to 2033
Figure 166: Middle East and Africa Market Value (US$ Million) Analysis by Indication , 2017 to 2033
Figure 167: Middle East and Africa Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033
Figure 168: Middle East and Africa Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033
Figure 169: Middle East and Africa Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2033
Figure 170: Middle East and Africa Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 171: Middle East and Africa Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 172: Middle East and Africa Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2033
Figure 173: Middle East and Africa Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 174: Middle East and Africa Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 175: Middle East and Africa Market Attractiveness by Vaccine Type, 2023 to 2033
Figure 176: Middle East and Africa Market Attractiveness by Valance, 2023 to 2033
Figure 177: Middle East and Africa Market Attractiveness by Indication , 2023 to 2033
Figure 178: Middle East and Africa Market Attractiveness by Route of Administration, 2023 to 2033
Figure 179: Middle East and Africa Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 180: Middle East and Africa Market Attractiveness by Country, 2023 to 2033
